
Sumary of Gov’t cautions public on ivermectin:
- Malacanang urged the public Tuesday to wait for regulator approval for Ivermectin, said to be useful for COVID-19 treatment and prevention, after a lawmaker said he planned to distribute the anti-parasitic drug..
- Justice Secretary Menardo Guevarra did not directly answer a question whether Defensor was violating the law, saying it is not a specific case before his office..
- “Generally speaking, it is prohibited, under the FDA law, to manufacture, import, export, sell, offer to sell, distribute, transfer, promote, advertise, etc… health products that are unregistered with the FDA,”.
- Also interviewed on Dobol B TV, Department of Health Undersecretary Maria Rosario Vergeire pointed out the anti-parasitic drug ivermectin is not yet registered and was still subject to the evaluation of the Food and Drug Administration..
- Meanwhile, World Health Organization country representative Rabindra Abeyasinghe said clinical trials should be conducted before making a conclusion whether or not the anti-parasitic drug ivermectin could treat COVID-19 patients..
- “The WHO came out with a very clear position that the potential use of ivermectin as a prophylactic or as a therapeutic agent needs to be evaluated through equally strong clinical trials, not just the solidarity trials,”.
- “Let do a clinical trial that has the power to differentiate whether what we have seen is because of chance, or there is the actual efficacy of the drug..
- At the same time, the DOH and Food and Drug Administration were discouraging the use of Ivermectin on COVID-19 patients amid calls for them to authorize the antiparasitic drug..
- The DOH and FDA said a study of six trials by reviewers from the Philippine COVID-19 Living Clinical Practice Guidelines found:.
- · Ivermectin was not associated with a definite benefit of other clinically important outcomes such as clinical improvement at Day 6-10, clinical deterioration, and need for mechanical ventilation;…